Melanoma has been a particular target of immunotherapy because of its inherent immunogenicity, and early therapeutic approaches such as interleukin-2 (IL-2) and interferon-alpha2b (IFNα2b) aimed to stimulate these antitumor immune responses (Mocellin et al., 2010; Rosenberg, 2014). Here, IL2 is linked to melanoma.